Organon & Co. has announced new data from a sub-analysis of pooled Phase 3 ADORING 1 and ADORING 2 trials evaluating VTAMA® (tapinarof) cream, 1%, for the treatment of atopic dermatitis in children aged 2 to 17 years. The results indicate that VTAMA cream provided early and consistent skin clearance, as well as improvements in key atopic dermatitis measures, regardless of comorbidity status such as asthma, allergic rhinitis, or food allergies. The most frequently reported treatment-emergent adverse events in this pediatric population were folliculitis (7.8%), upper respiratory tract infection (4.6%), and headache (3.7%). Improvements in patient-reported outcomes, including sleep and itch relief, were observed as early as week 1 and maintained through week 8. These findings will be presented at the 2025 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting in Orlando, Florida, on November 8, 2025.